Bepranemab

Roche ends partnership with UCB in Alzheimer’s disease, returning rights to Phase IIa prospect bepranemab, marking Roche’s second Alzheimer’s partnership cut this year. UCB announced the partnership termination as it prepares to present Phase IIa study results at the 2024 Clinical Trials on Alzheimer’s Disease Meeting. Roche, lagging in Alzheimer’s treatment development, continues to explore early-stage assets like RG6289 and trontinemab.

UCB's TOGETHER Phase 2a study results of bepranemab, an anti-tau antibody for prodromal to mild Alzheimer’s Disease, accepted for presentation at 2024 CTAD Meeting. Study highlights clinical, safety, and imaging endpoints, reflecting UCB's commitment to new Alzheimer's treatments. UCB regained global rights to bepranemab after terminating collaboration with Roche and Genentech.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.